Vijay Reddy
Affiliations: | University of Florida, Gainesville, Gainesville, FL, United States |
Area:
Biomedical Engineering, Cell BiologyGoogle:
"Vijay Reddy"
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Ludwig DL, Bryan RA, Dawicki W, et al. (2020) Preclinical Development of an Actinium-225-Labeled Antibody Radio-Conjugate Directed Against CD45 for Targeted Conditioning and Radioimmunotherapy Biology of Blood and Marrow Transplantation. 26 |
| Nath R, Chu B, Chen L, et al. (2020) Feasibility of Administering Anti-CD45 Iodine (131I) Apamistamab [Iomab-B] for Targeted Conditioning in Older Patients with Active, Relapsed or Refractory AML without Lead-Lined Rooms: Ongoing Phase III Sierra Trial Experience at 6 Study Sites Biology of Blood and Marrow Transplantation. 26 |
| Gyurkocza B, Nath R, Stiff PJ, et al. (2020) Targeted Conditioning with Anti-CD45 Iodine (131I) Apamistamab [Iomab-B] Leads to High Rates of Allogeneic Transplantation and Successful Engraftment in Older Patients with Active, Relapsed or Refractory (rel/ref) AML after Failure of Chemotherapy and Targeted Agents: Preliminary Midpoint Results from the Prospective, Randomized Phase 3 Sierra Trial Biology of Blood and Marrow Transplantation. 26 |
| Tomlinson BK, Reddy V, Berger MS, et al. (2019) Rapid reduction of peripheral blasts in older patients with refractory acute myeloid leukemia (AML) using reinduction with single agent anti-CD45 targeted iodine (131I) apamistamab [Iomab-B] radioimmunotherapy in the phase III SIERRA trial. Journal of Clinical Oncology. 37: 7048-7048 |
| Chu BP, Pandit-Taskar N, Gyurkocza B, et al. (2019) Feasibility of Administering Anti-CD45 Iodine (131I) Apamistamab [Iomab-B] for Re-Induction and Targeted Conditioning in Older Patients with Active, Relapsed or Refractory AML without Lead-Lined Rooms: Sierra Trial Experience at MSKCC Blood. 134: 5839-5839 |
| Nath R, Geoghegan EM, Ulrickson ML, et al. (2019) Sierra Clinical Trial Dosimetry Results Support Low Dose Anti-CD45 Iodine (131I) Apamistamab [Iomab-B] for Targeted Lymphodepletion Prior to Adoptive Cell Therapy Blood. 134: 1958-1958 |
| Ludwig D, Bryan R, Dawicki W, et al. (2019) Preclinical Development of an Actinium-225-Labeled Antibody Radio-Conjugate Directed Against CD45 for Targeted Conditioning and Radioimmunotherapy Blood. 134: 5601-5601 |
| Gyurkocza B, Nath R, Stiff PJ, et al. (2019) Re-Induction and Targeted Conditioning with Anti-CD45 Iodine (131I) Apamistamab [Iomab-B] Leads to High Rates of Transplantation and Successful Engraftment in Older Patients with Active, Relapsed or Refractory (rel/ref) AML after Failure of Chemotherapy and Targeted Agents: Preliminary Midpoint Results from the Prospective, Randomized Phase 3 Sierra Trial Blood. 134: 5642-5642 |
| Tomlinson BK, Reddy V, Berger MS, et al. (2019) Rapid Reduction of Peripheral Blasts in Older Patients with Refractory Acute Myeloid Leukemia (AML) Using Re-Induction with Single Agent Anti-CD45 Targeted Iodine (131I) Apamistamab [Iomab-B] Radioimmunotherapy in the Phase III SIERRA Trial Clinical Lymphoma, Myeloma & Leukemia. 19 |
| Nath R, Reddy V, Kapur A, et al. (2019) Survival of Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) Patients Receiving Stem Cell Transplantation (SCT) Biology of Blood and Marrow Transplantation. 25 |